10-K: Candel Therapeutics Advances Cancer Therapies, Secures Funding

Candel Therapeutics reports positive Phase 3 prostate cancer data, secures $100M royalty deal, and plans pivotal trials for lung cancer, extending its financial runway into Q1 2028.

Summary

• Aglatimagene besadenovec (CAN-2409) met its primary endpoint in a pivotal Phase 3 clinical trial for newly diagnosed, localized prostate cancer, demonstrating a statistically significant improvement in disease-free survival (DFS) (p=0.0155; HR 0.70; 95% CI; 0.52 to 0.94). Median DFS was not reached for the aglatimagene arm versus 86.1 months in the placebo arm.
• Aglatimagene received Regenerative Medicine Advanced Therapy (RMAT) Designation from the FDA for newly diagnosed, localized prostate cancer in intermediateto high-risk patients in May 2025.
• In a Phase 2a clinical trial for Non-Small Cell Lung Cancer (NSCLC), aglatimagene combined with immune checkpoint inhibitors (ICI) showed a median overall survival (mOS) of 24.5 months in patients with inadequate response to ICI, and 21.5 months in patients with progressive disease despite ICI, which is markedly longer than historical standard of care (SoC) chemotherapy (9.8-11.8 months).
• 37% of NSCLC patients with progressive disease were still alive > 24 months after aglatimagene treatment as of March 3, 2025 data cut.
• In a Phase 2a clinical trial for borderline resectable pancreatic ductal adenocarcinoma (PDAC), aglatimagene showed an estimated mOS of 31.4 months versus 12.5 months in the control group. 3 out of 7 patients in the aglatimagene group were still alive at the February 20, 2025 data cut-off, with survival of 66.0, 63.6, and 35.8 months after enrollment.
• Linoserpaturev (CAN-3110) in an investigator-sponsored Phase 1b clinical trial for recurrent high-grade glioma (HGG) demonstrated mOS of 11.8 months (Arm A, n=41) and 12.0 months (Arm B, n=9) after a single injection, compared to historical controls of <6-9 months.
• The company secured a $100 million royalty purchase agreement with RTW Investments, LP, contingent upon FDA marketing approval of aglatimagene for intermediate-risk and high-risk localized prostate cancer.
• A follow-on equity offering in February 2026 raised approximately $93.5 million in net proceeds.
• The company's existing cash and cash equivalents, combined with the proceeds from the 2026 Follow-On Offering, are expected to fund operations into the first quarter of 2028.
• Net loss for the year ended December 31, 2025, was $38.2 million, an improvement from $55.2 million in 2024.
• Research and development expenses increased by $11.2 million to $30.5 million in 2025, primarily due to increased manufacturing, clinical trial, and regulatory costs for aglatimagene programs.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as highly positive due to multiple product candidates showing significantly improved survival outcomes over standard of care in late-stage clinical trials, coupled with substantial recent financing that extends the operational runway and de-risks future development.

Positives

• Aglatimagene's pivotal Phase 3 trial in prostate cancer met its primary endpoint, showing a statistically significant 30% improvement in disease-free survival (HR 0.70, p=0.0155) compared to placebo.
• Aglatimagene demonstrated a statistically significant improvement in prostate cancer-specific DFS (HR 0.62, p=0.0046) in the Phase 3 prostate cancer trial.
• The Phase 3 prostate cancer trial showed a statistically significant increase in patients achieving a PSA nadir (<0.2 ng/ml) (67.1% vs. 58.6%, p=0.0164) and pathological complete response (80.4% vs. 63.6%, p=0.0015) in the aglatimagene arm.
• Aglatimagene was generally well tolerated across trials, with common adverse events being mild to moderate flu-like symptoms, fever, and chills, and no increase in serious adverse events versus placebo in the prostate cancer Phase 3 trial.
• Aglatimagene received FDA Fast Track Designation for localized, primary prostate cancer, NSCLC, and PDAC, and Regenerative Medicine Advanced Therapy (RMAT) Designation for newly diagnosed, localized prostate cancer.
• Aglatimagene in NSCLC Phase 2a showed a markedly longer median overall survival (mOS) of 24.5 months (all inadequate ICI response) and 21.5 months (progressive disease despite ICI) compared to historical SoC chemotherapy (9.8-11.8 months).
• 37% of NSCLC patients with progressive disease treated with aglatimagene were still alive > 24 months, suggesting a 'long tail of survival'.
• Aglatimagene in PDAC Phase 2a demonstrated an estimated mOS of 31.4 months versus 12.5 months in the control group, with 3 out of 7 patients still alive at the data cut-off (66.0, 63.6, and 35.8 months after enrollment).
• Linoserpaturev received FDA Fast Track Designation and Orphan Drug Designation for recurrent HGG.
• Linoserpaturev in recurrent HGG Phase 1b showed mOS of 11.8-12.0 months, markedly longer than historical controls (<6-9 months), with evidence of immune activation and long-term survivors (59.2 and 42.4 months).
• The enLIGHTEN Discovery Platform is generating novel viral immunotherapy candidates, with preclinical data showing monotherapy activity and combination activity with ICIs.
• The company secured a $100 million royalty purchase agreement with RTW Investments, LP, providing significant non-dilutive funding upon FDA approval of aglatimagene in prostate cancer.
• A February 2026 follow-on equity offering generated approximately $93.5 million in net proceeds, extending the company's cash runway into Q1 2028.
• Net loss decreased from $55.2 million in 2024 to $38.2 million in 2025, and interest income increased significantly due to higher cash equivalents.

Negatives

• The Phase 2 clinical trial of aglatimagene monotherapy in lowto intermediate-risk prostate cancer did not reach statistical significance for its primary endpoint (progression-free survival), potentially due to being underpowered, a high percentage of low-risk patients, and fewer administrations than the Phase 3 trial.
• The company decided to pause further clinical development of aglatimagene in PDAC, in the context of portfolio prioritization, unless externally funded through a grant or other non-dilutive external funding.
• The company has a limited operating history and has not generated any revenue from product sales to date, expecting significant expenses and operating losses for the foreseeable future.
• The company has incurred indebtedness under the Trinity LSA and may incur additional indebtedness, which could adversely affect its financial condition and operating flexibility.
• The former CEO, Dr. Aguilar-Cordova, was notified of alleged instructions to falsify sterility testing results and failure to implement an appropriate stability testing program for aglatimagene, though the company states no risk to clinical data integrity or patient safety.

Risks

• The company is a biopharmaceutical company with a limited operating history and has not generated any revenue from product sales, expecting significant expenses and increasing operating losses for the foreseeable future.
• Substantial additional funding will be needed, and if unavailable on acceptable terms, product development programs or commercialization efforts may be delayed, reduced, or eliminated, or operations may cease.
• Indebtedness, including the Trinity LSA, could adversely affect financial condition and operating flexibility, with covenants limiting actions like incurring additional debt or granting liens.
• The business is dependent on the success of aglatimagene and linoserpaturev, which require additional development and may not receive regulatory approval or achieve commercial success.
• Preclinical studies and clinical trials may fail to demonstrate adequate safety and efficacy, preventing or delaying development, regulatory approval, and commercialization.
• Product candidates are based on a novel approach to cancer treatment, making it difficult to predict the time and cost of development and regulatory approval.
• Even if approved, product candidates may not achieve broad market acceptance, limiting revenue generation.
• The regulatory approval processes are lengthy, time-consuming, and unpredictable, potentially delaying or preventing commercialization.
• FDA's Special Protocol Assessment for aglatimagene's Phase 3 prostate cancer trial does not guarantee regulatory approval and may not lead to a successful review.
• Some product candidates are studied in third-party or investigator-sponsored trials, over which the company has minimal or no control, potentially affecting marketing approval or exclusivities.
• Changes in product candidate manufacturing or formulation may result in additional costs or delays.
• Future public health crises or geopolitical conflicts may adversely affect business and operations.
• Failure of government or third-party payors to provide adequate coverage, reimbursement, and payment rates for product candidates would limit revenue and profitability.
• Reliance on third-party manufacturers for timely production and compliance with regulations poses risks of delays, inability to meet demand, and lost revenues.
• The transition of manufacturing operations to a third-party contract manufacturer may result in delays or expenses and may not achieve anticipated operating efficiencies.
• Rights to develop and commercialize certain product candidates are subject to third-party licenses, and failure to comply with obligations could lead to loss of intellectual property rights.
• The price of common stock may be volatile and fluctuate substantially, leading to potential losses for stockholders.
• Raising additional capital through equity sales could dilute stockholders and cause stock price decline.
• The company's status as an emerging growth company and smaller reporting company allows for reduced disclosure requirements, which could make common stock less attractive to investors.
• Increased costs associated with operating as a public company and compliance initiatives may divert management's time and resources.
• Potential product liability exposure from clinical trials and commercial sales could result in substantial liability.
• Noncompliance with anti-corruption laws, import/export controls, and other laws governing operations could lead to civil or criminal penalties.
• Failure to comply with federal and state healthcare laws, including fraud and abuse and privacy laws, could result in substantial penalties.
• Use of new and evolving technologies, such as artificial intelligence, may present cybersecurity, data privacy, IT, intellectual property, regulatory, legal, operational, competitive, and reputational risks.
• Failure to comply with environmental, health, and safety laws and regulations could lead to fines or penalties.
• Dependence on development and commercialization collaborators exposes the company to risks if collaborators fail to perform as expected.
• Conflicts with collaborators or licensors may arise, potentially adverse to the company's interests.
• Reliance on third parties for clinical trials and manufacturing means limited control over their performance and compliance.
• Inadequate patent terms or inability to protect intellectual property rights globally could harm competitive position.
• Third-party claims of intellectual property infringement may prevent or delay product development.

Future Outlook

The company anticipates submitting a Biologics License Application (BLA) for aglatimagene in prostate cancer in the fourth quarter of 2026. A pivotal Phase 3 clinical trial for aglatimagene in progressive, metastatic, non-squamous NSCLC is planned for initiation in the second quarter of 2026. Enabling work for a potential future randomized controlled Phase 2 dose regimen finding study of linoserpaturev in recurrent glioblastoma has begun. The company expects to announce supportive data on prostate cancer-specific outcomes in Q2 2026 and immunological biomarker data in Q3 2026. Updated OS data and long-term survival analysis from the Phase 2a NSCLC trial are expected in Q1 2026, and mature mOS data for linoserpaturev Arm C in HGG are expected in Q4 2026. Existing financial resources, including recent capital raises, are projected to fund operations into the first quarter of 2028.

Management Comments

• Management believes viral immunotherapy is among the most promising cancer treatment modalities today, aiming to further improve patient outcomes by selecting optimal vectors, transgenes, and clinical indications.
• Management believes that, if approved, aglatimagene could be a first-in-class drug for localized prostate cancer patients, and is preparing for commercialization with a capital-efficient model focused on partner networks and relationships with leading investigators, treatment centers, patient advocacy groups, and payers.
• Management views the positive findings from the NSCLC trial as a basis to initiate a pivotal Phase 3 clinical trial for aglatimagene in patients with progressive, metastatic, non-squamous NSCLC.
• Management believes linoserpaturev provides a significant opportunity for therapeutic use in recurrent HGG based on observed survival benefits.
• Management is confident that the enLIGHTEN Discovery Platform will enable rapid vector engineering and generate new candidates in a data-driven and indication-specific manner, leveraging computational biology and artificial intelligence.

Industry Context

StockSavvy.ai notes that Candel Therapeutics is operating within the highly competitive immuno-oncology and viral immunotherapy space. The company's focus on 'off-the-shelf' viral immunotherapies that induce systemic anti-tumor responses aligns with a growing trend to enhance the body's own immune system to fight cancer. The strategy of combining viral immunotherapies with existing standard of care treatments like radiotherapy and immune checkpoint inhibitors (ICIs) is a recognized approach to overcome resistance and improve outcomes in 'cold' tumors, which are typically less responsive to ICIs alone. The development of novel viral immunotherapy candidates through platforms like enLIGHTEN, leveraging AI and computational biology, reflects the industry's push towards more targeted and efficient drug discovery.

Comparison to Industry Standards

• Aglatimagene's mOS of 24.5 months in NSCLC patients with inadequate response to ICI is markedly longer than the 9.8-11.8 months mOS reported in published literature for similar patients receiving standard of care docetaxel second-line chemotherapy.
• Aglatimagene's estimated mOS of 31.4 months in borderline resectable PDAC significantly exceeds the 12.5 months observed in the control group receiving standard of care chemotherapy.
• Linoserpaturev's mOS of 11.8-12.0 months in recurrent HGG is markedly longer than the <6-9 months mOS typically observed in historical clinical trials of other investigational agents in this difficult-to-treat patient population.
• The observed pathological complete response rate of 80.4% in aglatimagene-treated prostate cancer patients in 2-year post-treatment biopsies compares favorably to 37%-73% reported in control populations in previous Phase 2a data.

Management Changes

Corporate Governance

Legal Proceedings

• No current litigation or legal proceedings that, in management's opinion, are probable to have a material adverse effect on the business.

Related Party Transactions

• Exclusive licensing agreement with Ventagen, LLC (a related party) for product development and commercialization in Mexico, Belize, Guatemala, Honduras, El Salvador, Costa Rica, Nicaragua, Panama, Colombia, and Bolivia.
• Amendment to Series B Warrants and Conditional Series B Warrants on October 14, 2025, involved holders including affiliates of Paul Manning and Chris Martell, who are directors of the Company.

Stakeholder Impact

• Shareholders: Potential for significant value creation if aglatimagene receives FDA approval and achieves commercial success, especially given the $100M royalty deal and recent equity raise. However, dilution from future capital raises remains a risk.
• Employees: New 2025 Inducement Plan aims to attract and retain key talent through equity awards, fostering alignment with company success.
• Patients: Positive clinical trial results for aglatimagene and linoserpaturev offer potential new therapeutic options for prostate cancer, NSCLC, PDAC, and HGG, addressing significant unmet medical needs.
• Creditors: The Trinity LSA and RTW Purchase Agreement introduce new debt and royalty obligations, which could impact the company's financial flexibility and cash flow, but also provide necessary capital for development.

Next Steps

• Announce supportive data on prostate cancer-specific outcomes (prostate cancer-specific DFS, time to salvage anti-cancer therapy, and time to metastasis) after extended follow-up in the second quarter of 2026.
• Present novel immunological biomarker data in patients with localized prostate cancer in the third quarter of 2026.
• Submit a Biologics License Application (BLA) for aglatimagene in prostate cancer in the fourth quarter of 2026.
• Initiate a pivotal Phase 3 clinical trial of aglatimagene in patients with progressive, metastatic, non-squamous NSCLC despite ICI treatment in the second quarter of 2026.
• Announce updated data on OS including data on long-term survival and biomarker analysis from the Phase 2a clinical trial in NSCLC in the first quarter of 2026.
• Perform enabling work for a potential future randomized controlled Phase 2 dose regimen finding study of linoserpaturev in recurrent glioblastoma, following IND clearance in January 2026.
• Present mature mOS data and an update on long-term survivors from Arm C of the linoserpaturev trial in the fourth quarter of 2026.

Key Dates

Recommendation

The company has reported highly compelling positive clinical data for its lead product candidate, aglatimagene, in multiple significant oncology indications (prostate cancer, NSCLC, PDAC), demonstrating superior efficacy compared to standard of care. The Phase 3 success in prostate cancer, coupled with RMAT designation and an anticipated BLA submission in Q4 2026, positions aglatimagene for potential first-in-class approval in a large market. The $100 million royalty purchase agreement with RTW Investments, LP, contingent on this approval, provides a clear path to non-dilutive funding. Additionally, linoserpaturev shows promising survival benefits in recurrent HGG, an area of high unmet need. Recent capital raises have extended the cash runway, mitigating immediate liquidity concerns. While risks inherent in biopharmaceutical development exist, the breadth and strength of the clinical data, regulatory designations, and strategic financing significantly de-risk the investment and point to substantial upside potential.

Keywords

Candel Therapeutics, aglatimagene besadenovec, CAN-2409, linoserpaturev, CAN-3110, viral immunotherapy, oncolytic virus, prostate cancer, NSCLC, pancreatic cancer, high-grade glioma, HGG, glioblastoma, Phase 3 clinical trial, Phase 2a clinical trial, FDA approval, RMAT Designation, Fast Track Designation, Orphan Drug Designation, disease-free survival, overall survival, immunotherapy, cancer treatment, biopharmaceutical, oncology, adenovirus, herpes simplex virus, HSV, enLIGHTEN Discovery Platform, capital raise, royalty agreement, SEC filing, 10-K